Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Epirubicin · 1 trial · 1 indication
Within 3-4 weeks after last docetaxel dose the surgery was performed to evaluate pathological response. According to the Miller\&Payne Criteria, pCR in node-negative patients is a grade 5-A and in node-positive patients is a grade 5-D.
| Arm | Type | Description |
|---|---|---|
| Experimental | EXPERIMENTAL | Epirubicin + Cyclophosphamide -\> Docetaxel + Lapatinib |
| Control | ACTIVE_COMPARATOR | Epirubicin + Cyclophosphamide -\> Docetaxel + Trastuzumab |
| Name | Type | Description |
|---|---|---|
| Epirubicin | DRUG | - |
| Cyclophosphamide | DRUG | - |
| Docetaxel | DRUG | - |
| Lapatinib | DRUG | - |
| Trastuzumab | DRUG | - |
Inclusion Criteria: 1. Signature of the written informed consent. 2. Histological documentation of breast cancer. 3. Stage I (T1, N0M0), IIA (T2N0M0); IIB (T2N1M0, T3N0M0), IIIA (TXN2M0) and IIIB (T3N1M0, T4NXM0) primary resectable breast cancer or locally advanced breast cancer. 4. HER2-positive b...
Top 20 of 92 competitors
Epirubicin is a small molecule oncology drug being studied for the treatment of breast cancer. It is currently in Phase 2 clinical development as an investigational therapy. In the completed clinical trial, it was evaluated in patients with HER2-positive breast cancer as part of a neoadjuvant treatment regimen.
Epirubicin is being developed by GSK plc, a pharmaceutical company listed on the stock exchange under the ticker symbol GSK. The company is conducting clinical research to evaluate the drug's safety and efficacy in treating breast cancer.
Epirubicin is currently in Phase 2 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. One Phase 2 clinical trial has been completed, and the drug is not currently in any active trials.
Epirubicin has been studied in one completed Phase 2 clinical trial with the identifier NCT00841828. The trial, titled 'Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients', enrolled 102 female patients with breast cancer in Spain. The trial was randomized and active-controlled, and it included biomarker selection.
Epirubicin is not known to have any alternative names. It is a distinct drug entity being developed by GSK plc for the treatment of breast cancer. Its mechanism of action has not been specified in the available information.